Sucampo Pharmaceuticals — Corporate Update (December 2013)
9 slides from Sucampo Pharmaceuticals's corporate update, Dec 17, 2013
Slide 1: Continued AMITIZA YOY Growth
Continued AMITIZA YOY Growth + Takeda reported Q3 net sales at $72.5M*; 3.5% YoY increase in net sales to $204M through September + Growth trend continued as October reached highest TRx on record for AMITIZA — up 4% in October YoY to 117K! OIC Opportunity * 40-80% of non-cancer patients on chronic o
Slide 2: Sucampo Prostone Pipeline Key Highlights
Sucampo Prostone Pipeline Key Highlights AMITIZA Clinical Development & Life Cycle Management New liquid dosage form + Initiated liquid formulation pivotal trial in CIC in adults . October 2013; alternative treatment for patients who prefer not to take capsules + Takeda funding 100% of development c
Slide 3: Clinical Pipeline & Product Development Highlights
Clinical Pipeline & Product Development Highlights CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT LEAD COMPOUNDS PRECLINICAL | PHASE 1 PHASE 2 PHASE 3 Lubiprostone Liquid Formulation CIC Unoprostone Isopropyl Retinitis Pigmentosa* TE a a | Lubiprostone Pediatric Functional Constipation PO Ion Channel
Slide 4: Key Facts & Financial Highlights
Key Facts & Financial Highlights Key Facts Trading Symbol SCMP (NASDAQ) Corporate Headquarters Bethesda, MD Stock Price (12-13-13), 52-Week Range $7.72, $10.48 to $4.55 Shares O ing (12-13-13) 43.3M (1 class of common stock) Daily Volume (90-day average) 129,896 Market Capitalization (12-13-13) $334
Slide 5: Global Goals and Milestones
: Ne Global Q y v AMITIZA pescua| us| v v Tn Cc st we Pipeline | Cobiprostone (9 lon inel i Y Completed O In Progress Obtain approval of OIC sNDA: 1Q 2013 $10M milestone payment upon commercial launch of OIC Pursue strategic alli new AMITIZA indicati i Grow sales in Japan in 2013 Submit for regulato
Slide 6: Upcoming Catalysts
Top-line results of phase 2a trial of IV ion channel activator for Lumbar Spinal Stenosis CEO Transition (EST) AMITIZA OIC indication potential approval in Switzerland / U.K. ¢€ 3 SUCAMPO The Scien
Slide 7: Key Facts & Financial Highlights
Key Facts & Financial Highlights ncial High 9 Months of hts as of Trading Symbol SCMP (NASDAQ) 2013) Corporate Headquarters _| Bethesda, MD Dept S270M Stock Price (12-13-13), §2- | $7.72, $10.48 to Cash & Equivalents $51 0M Week Range $4.55 Total Operating Expense | $49.1M Shares Outstanding (12-13-
Slide 8: Patent listing: lubiprostone and unoprostone
4932316 2023 ‘Composion of mater (drug substance and drug product) 4.092,59 2028 Therapeute use (reatng OIC) oe 7 “Therapeutic use (veatng conetpaton) “4.78,794 2028 ‘Composton of mater (ug produt) 7766086 2028 ‘Therapeute use (woaing Constpaton) 4,852,209 2028 Therapeutic use (eating constipation)
Slide 9: References
References 4. IMS Smart View, NPA Report, client Factored Numbers, September 2012-October 2013, Camilier challenges and. Ams ot Clearview Analysis 2008 2 3 4. Internal Research 5. AMITIZA Physician ATU Wit 2013 6. Fingertip Formulary (NOV 2013) 7. IMS Smart View, RAPID Weekly, Client Factored Number
Sucampo Pharmaceuticals — Corporate Update (December 2013) on 6ix